These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 16787887)

  • 1. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome.
    Shirzadi AA; Ghaemi SN
    Harv Rev Psychiatry; 2006; 14(3):152-64. PubMed ID: 16787887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Movement disorders associated with neuroleptic treatment.
    Wirshing WC
    J Clin Psychiatry; 2001; 62 Suppl 21():15-8. PubMed ID: 11584982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motor and mental side effects of clozapine.
    Gerlach J; Peacock L
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():107-9. PubMed ID: 7961551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of antiparkinson agents in preventing antipsychotic-induced extrapyramidal symptoms.
    Murphy JE; Stewart RB
    Am J Hosp Pharm; 1979 May; 36(5):641-4. PubMed ID: 36755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Extrapyramidal effects of antipsychotic drugs].
    Kulisevsky J; Otermin P
    Neurologia; 2003 Jun; 18(5):262-8. PubMed ID: 12768512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():23-7. PubMed ID: 9766616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of schizophrenia with obesity, metabolic, and endocrinological disorders.
    Monteleone P; Martiadis V; Maj M
    Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder.
    Gentile S
    J Clin Psychopharmacol; 2007 Feb; 27(1):35-45. PubMed ID: 17224710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects.
    Jafari S; Fernandez-Enright F; Huang XF
    J Neurochem; 2012 Feb; 120(3):371-84. PubMed ID: 22103329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extrapyramidal syndromes caused by antipsychotics.
    Jesić MP; Jesić A; Filipović JB; Zivanović O
    Med Pregl; 2012; 65(11-12):521-6. PubMed ID: 23297621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of acute neuroleptic-induced movement disorders.
    Tonda ME; Guthrie SK
    Pharmacotherapy; 1994; 14(5):543-60. PubMed ID: 7997388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes.
    Silvestre JS; Prous J
    Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):289-304. PubMed ID: 16082416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
    Nasrallah HA; Brecher M; Paulsson B
    Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment.
    Gerlach J
    J Clin Psychiatry; 1999; 60 Suppl 23():20-4. PubMed ID: 10625196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Extrapyramidal side-effects: avoidance, diagnosis and treatment].
    Fleischhacker WW; Widschwendter C
    Psychiatr Prax; 2005 Apr; 32 Suppl 1():S25-30. PubMed ID: 15818517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship of pharmacology to side effects.
    Casey DE
    J Clin Psychiatry; 1997; 58 Suppl 10():55-62. PubMed ID: 9265918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles.
    Nasrallah HA
    Mol Psychiatry; 2008 Jan; 13(1):27-35. PubMed ID: 17848919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
    Newcomer JW
    J Clin Psychiatry; 2007; 68 Suppl 1():20-7. PubMed ID: 17286524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurological complications of psychiatric drugs: clinical features and management.
    Haddad PM; Dursun SM
    Hum Psychopharmacol; 2008 Jan; 23 Suppl 1():15-26. PubMed ID: 18098217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risks of atypical antipsychotic drug treatment.
    Drici MD; Priori S
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):882-90. PubMed ID: 17563919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.